Search

Displaying results 3901 - 3910 of 5897 in total
  1. Drug

    3-Fluoro-L-tyrosine

    go.drugbank.com/drugs/DB04436
    Experimental

    This compound belongs to the phenylpropanoic acids. … These are compounds whose structure contain a benzene ring conjugated to a propanoic acid. 3-Fluoro-L-tyrosine targets the protein superoxide dismutase [mn], mitochondrial.

  2. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

  3. Drug

    TGAAC09

    go.drugbank.com/drugs/DB06363
    Investigational

    tgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins.

  4. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. … [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity

  5. Drug

    Dichlorophen

    go.drugbank.com/drugs/DB11396
    InvestigationalVet approved

    Dichlorophen is an antimicrobial agent shown to exert activity against cestodes, protozoa, fungi, and bacteria. … It is often combined with toluene to remove parasites including ascarids, tapeworm, and hookworm from dogs and cats.

  6. Drug

    Brodimoprim-4,6-Dicarboxylate

    go.drugbank.com/drugs/DB02809
    Experimental

    This compound belongs to the anisoles. These are organic compounds contaiing a methoxybenzene or a derivative thereof. This medication is known to target the protein dihydrofolate reductase.

  7. Drug

    Clinafloxacin

    go.drugbank.com/drugs/DB14025
    Experimental

    It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.

  8. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  9. Drug

    Rilematovir

    go.drugbank.com/drugs/DB15672
    Investigational

    Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With

  10. Drug

    Rindopepimut

    go.drugbank.com/drugs/DB05374
    Investigational

    Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).